XOMA Corp (NASDAQ:XOMA) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of XOMA Corp (NASDAQ:XOMA) have received a consensus rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $23.75.

XOMA has been the topic of several research analyst reports. ValuEngine upgraded shares of XOMA from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. HC Wainwright set a $30.00 price objective on shares of XOMA and gave the stock a “buy” rating in a report on Friday, June 14th. Finally, Wedbush reiterated a “buy” rating and issued a $25.00 price objective on shares of XOMA in a report on Thursday.

In other XOMA news, major shareholder Bvf Partners L. P/Il acquired 3,797 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average cost of $14.36 per share, for a total transaction of $54,524.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Value Fund L. P. Biotechnology acquired 27,913 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was acquired at an average price of $14.63 per share, with a total value of $408,367.19. The disclosure for this purchase can be found here. Insiders purchased 42,010 shares of company stock valued at $612,963 over the last quarter. 9.89% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the stock. California Public Employees Retirement System boosted its holdings in XOMA by 11.5% in the fourth quarter. California Public Employees Retirement System now owns 11,860 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,220 shares in the last quarter. Pennsylvania Trust Co bought a new stake in XOMA in the first quarter worth $3,531,000. Bank of New York Mellon Corp boosted its holdings in XOMA by 19.0% during the fourth quarter. Bank of New York Mellon Corp now owns 60,173 shares of the biotechnology company’s stock valued at $761,000 after acquiring an additional 9,613 shares during the period. BlackRock Inc. boosted its holdings in XOMA by 12.4% during the fourth quarter. BlackRock Inc. now owns 508,672 shares of the biotechnology company’s stock valued at $6,434,000 after acquiring an additional 56,130 shares during the period. Finally, Two Sigma Advisers LP boosted its holdings in XOMA by 9.9% during the fourth quarter. Two Sigma Advisers LP now owns 32,195 shares of the biotechnology company’s stock valued at $407,000 after acquiring an additional 2,905 shares during the period. Hedge funds and other institutional investors own 47.85% of the company’s stock.

Shares of XOMA stock traded down $0.32 on Friday, hitting $17.29. 34,513 shares of the company traded hands, compared to its average volume of 69,888. The stock’s 50-day moving average is $17.17. The company has a debt-to-equity ratio of 1.13, a quick ratio of 7.20 and a current ratio of 7.20. XOMA has a 12-month low of $11.02 and a 12-month high of $25.75. The company has a market cap of $159.31 million, a P/E ratio of -10.87 and a beta of 1.29.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported $0.21 EPS for the quarter, beating the consensus estimate of ($0.12) by $0.33. XOMA had a negative net margin of 48.62% and a negative return on equity of 51.66%. The business had revenue of $8.13 million for the quarter, compared to analysts’ expectations of $3.23 million. Equities analysts expect that XOMA will post -1.09 EPS for the current fiscal year.

About XOMA

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Read More: What is a growth and income fund?

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.